摘要
目的探讨甲磺酸阿帕替尼治疗晚期恶性肿瘤的临床效果。方法选取晚期恶性肿瘤患者257例作为研究对象,所有患者均有行二线或二线以上治疗史。对照组患者进行最佳支持治疗,观察组在最佳支持治疗基础上应用甲磺酸阿帕替尼片进行治疗。评价疗效、生存期及观察药物毒副作用。结果观察组患者CEA、CYFRA21-1、VEGF、MMP-9水平低于对照组,有统计学意义(P<0.05)。观察组治疗有效率高于对照组,2组有统计学差异(P<0.05)。观察组主要毒副作用为高血压、骨髓抑制、乏力、手足综合征、蛋白尿等反应。结论甲磺酸阿帕替尼治疗晚期恶性肿瘤的临床效果较好,不良反应较轻,临床应用价值较高,值得推荐。
Objective To investigate the clinical effect of apatinib in the treatment of advanced malignant tumors. Meth- ods 257 patients with advanced malignant tumor were selected. All patients had a history of second-line or over second-line treatment, and the best supportive treatment was performed in the control group. The observation group was treated with the apatinib tablet in the best supportive treatment. Efficacy, survival and drug toxicities were observed. Results The levels of CEA, CY- FRA21-1, VEGF and MMP-9 in the observation group were significantly lower than those of the control group （ P 〈 0.05 ）. The effective rate of treatment group was higher than that of the control group （P 〈 0.05） ; The main side effects of the observation group were hypertension, bone marrow suppression, fatigue, hand, foot syndrome, proteinuria and other reactions. Conclusion Apatinib is an effective for advanced malignant tumors ,with relatively mild adverse reaction and high clinical value, and should be recommended.
出处
《实用癌症杂志》
2018年第2期343-345,共3页
The Practical Journal of Cancer
